When was Leukemia & Lymphoma Society founded?

Leukemia & Lymphoma Society was founded in 1949.

Who is the CEO of Leukemia & Lymphoma Society?

E. Anders Kolb is the CEO of Leukemia & Lymphoma Society.

Where is Leukemia & Lymphoma Society headquartered?

Leukemia & Lymphoma Society is headquartered in Rye Brook, NY.

How many investments has Leukemia & Lymphoma Society made?

Leukemia & Lymphoma Society has made 26 investments.

What has Leukemia & Lymphoma Society invested in?

Leukemia & Lymphoma Society has made numerous investments in companies like ViTToria Biotherapeutics , Enterome , and Dimericon Therapeutics within the Drug Discovery and Biotechnology industries.

What has Leukemia & Lymphoma Society invested in recently?

Leukemia & Lymphoma Society's latest investment was on 01-Jan-2024 in ViTToria Biotherapeutics , a company within the Drug Discovery industry.

Leukemia & Lymphoma Society Investor Profile: Portfolio & Exits

Leukemia & Lymphoma Society Overview

Investor Type

Venture Capital

Status

Active

Professionals

8

Investments

26

Portfolio

14

Exits

8

Leukemia & Lymphoma Society General Information

Company Description

Founded in 1949, Leukemia & Lymphoma Society is a nonprofit investment firm headquartered in Rye Brook, New York. The firm seeks to invest in the blood cancer therapeutics and healthcare sectors.

Business Details

Website

www.lls.org

Formerly Known As

Leukemia Society of America, Inc., Leukemia Society, Inc., Robert Roesler de Villiers Foundation, Inc.

Year Founded

1949

Investor Status

Actively Seeking New Investments

Primary Investor Type

Not-For-Profit Venture Capital

Corporate Office

3 International Drive
Suite 200
Rye Brook, NY 10573
United States

+1 (888) 000-0000







Leukemia & Lymphoma Society Investments (26)

Company Name	Deal Date	Deal Type	Deal Size	Industry	Company Stage	Lead Partner
ViTToria Biotherapeutics	01-Jan-2024	Early Stage VC	00.000	Drug Discovery	Pre-Clinical Trials
Enterome	30-Oct-2023	000000000000	00.000	Drug Discovery	Clinical Trials - Phase 2	0000 0000000
Enterome	25-Oct-2023	00000 00000	000.00	Drug Discovery	Clinical Trials - Phase 2
Dimericon Therapeutics	01-May-2023	0000 00000	00.00	Biotechnology	Stealth
BioInvent International	17-Jan-2023	0000	000	Drug Discovery	Generating Revenue/Not Profitable
Immune-Onc Therapeutics	05-Jan-2023	00000 00000	0000	Drug Discovery	Clinical Trials - Phase 2
Rgenta Therapeutics	29-Nov-2022	00000 00000	0000	Drug Discovery	Generating Revenue
Dren Bio	01-Nov-2022	00000 00000		Biotechnology	Generating Revenue
Abintus Bio	15-Aug-2022	Early Stage VC	000.00	Drug Discovery	Pre-Clinical Trials
Faron Pharmaceuticals	28-Jun-2022	PIPE	00.000	Drug Discovery	Generating Revenue

You’re viewing 10 of 26 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Leukemia & Lymphoma Society Exits (8)

Company Name	Exit Date	Exit Type	Exit Size
Kymera Therapeutics	05-Jan-2024	Public Investment 2nd Offering	00000
Caribou Biosciences	14-Jul-2023	000000 00000	00000
Carisma Therapeutics	07-Mar-2023	0000000 0000	00000
Protocol First	16-Dec-2021	000000000000
Selvita	16-Oct-2019	000
Forty Seven	28-Jun-2018	000	00000
Valor Biotherapeutics	01-Dec-2017	Out of Business
Acetylon Pharmaceuticals	16-Dec-2016	Merger/Acquisition	00000

To view Leukemia & Lymphoma Society’s complete exits history, request access »

Leukemia & Lymphoma Society Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.